Home / Companies / CARA Therapeutics, Inc. / 4 Jun 2024
CARA Therapeutics, Inc.: meeting of 4 Jun 2024
Votes reported on Form N-PX, item by item
164 Form N-PX filers reported votes at the CARA Therapeutics, Inc. meeting of 4 Jun 2024. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 71.0% of reported votes for; 29 filers withheld from or voted against at least one nominee.
162 vote records from 50 filers. 0 of the 49 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
211 vote records from 163 filers. 113 of the 154 filers that marked the item either way voted against management. 9 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
81 vote records from 50 filers. 0 of the 49 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
0 filers reported share counts too large to be the holding described. No share split is published for this item. How that is decided
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
162 vote records from 50 filers. 0 of the 49 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | Split or no vote | Against * | For |
| Fidelity | For | Against * | For |
| Dimensional | No report | Against * | No report |
| State Street and SPDR | For | For | For |
| Franklin Templeton | Split or no vote | Against * | For |
| Invesco | No report | Against * | No report |
| Equitable | Split or no vote | Against * | For |
| Charles Schwab | For | Against * | For |
| Nuveen and TIAA | For | Against * | For |
| ProShares and ProFunds | Split or no vote | Against * | For |
| John Hancock and Manulife | Split or no vote | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | Split or no vote | Against * | For |
| J.P. Morgan | No report | Against * | No report |
| Goldman Sachs | No report | Against * | No report |
| PGIM and Prudential | No report | Against * | No report |
| Northern Trust and FlexShares | For | For | For |
| SEI | For | Against * | For |
| T. Rowe Price | For | Against * | For |
| Lincoln Financial | For | For | For |
| Voya | Split or no vote | Against * | For |
| Nationwide | Split or no vote | Against * | For |
| Guggenheim and Rydex | Split or no vote | Against * | For |
| BNY Mellon | No report | Against * | No report |
| Principal | Split or no vote | Against * | For |
| Pacific Life funds | Split or no vote | Against * | For |
| Global X | For | Against * | For |
| Federated Hermes | No report | For | No report |
| AllianceBernstein | No report | Against * | No report |
| DWS | Split or no vote | Against * | For |
| Neuberger Berman | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the CARA Therapeutics, Inc. meeting?
164 Form N-PX filers reported votes at the meeting of 4 Jun 2024. On say-on-pay, 113 of 154 voted against management (73.4%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by CARA Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for CARA Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing CARA Therapeutics, Inc. with a meeting date within three days of 4 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.